THE RACE FOR CANCER DRUGS - If AstraZeneca's Iressa gets an FDA nod as early as June, ImClone's Erbitux will be left in the dust
| Year of publication: |
2002
|
|---|---|
| Published in: |
Business week / European edition : BW. - New York, NY : McGraw-Hill, ISSN 0007-7135, ZDB-ID 2402762. - 2002 (27.05.), p. 39
|